Tiziana Life Sciences (TLSA) said Thursday it does not intend to embark on any capital raising activity "for the immediate future."
The company said the decision comes after the news that came out on Wednesday about the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis treated with nasal foralumab.
Tiziana said it continues to be committed to delivering shareholder value and advancing its drug candidates via clinical trials and regulatory processes.
Tiziana shares fell 10% in recent trading.
Price: 0.72, Change: -0.08, Percent Change: -10.01
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。